Roche (OTCMKTS:RHHBY) Rating Reiterated by Societe Generale

Last updated on Tuesday, July 27, 2021 | 2021 MarketBeat

Roche (OTCMKTS:RHHBY)'s stock had its "hold" rating restated by research analysts at Societe Generale in a research report issued to clients and investors on Tuesday, The Fly reports.

Several other analysts have also commented on RHHBY. Cowen began coverage on Roche in a report on Wednesday, July 21st. They set an "outperform" rating on the stock. Morgan Stanley reissued an "equal weight" rating on shares of Roche in a report on Thursday, June 10th. Barclays set a $46.42 price objective on Roche and gave the company an "overweight" rating in a report on Friday. Berenberg Bank reissued a "hold" rating on shares of Roche in a report on Monday, June 14th. Finally, Deutsche Bank Aktiengesellschaft raised Roche from a "hold" rating to a "buy" rating in a report on Thursday, July 8th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and four have issued a buy rating to the company's stock. The company presently has an average rating of "Hold" and a consensus target price of $45.71.

Roche stock traded down $0.27 during midday trading on Tuesday, hitting $46.76. 1,725,426 shares of the company were exchanged, compared to its average volume of 992,171. The company has a market cap of $322.08 billion, a price-to-earnings ratio of 17.65, a PEG ratio of 2.20 and a beta of 0.33. Roche has a fifty-two week low of $39.72 and a fifty-two week high of $48.79. The stock's fifty day simple moving average is $46.36. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.30 and a quick ratio of 1.01.

A number of large investors have recently bought and sold shares of the business. Meeder Asset Management Inc. raised its position in Roche by 55.5% in the first quarter. Meeder Asset Management Inc. now owns 684 shares of the company's stock valued at $28,000 after purchasing an additional 244 shares during the period. First Horizon Advisors Inc. raised its position in Roche by 58.2% in the first quarter. First Horizon Advisors Inc. now owns 726 shares of the company's stock valued at $28,000 after purchasing an additional 267 shares during the period. Thomas White International Ltd. raised its position in Roche by 0.8% in the first quarter. Thomas White International Ltd. now owns 57,312 shares of the company's stock valued at $2,325,000 after purchasing an additional 464 shares during the period. Canandaigua National Corp raised its position in Roche by 2.7% in the first quarter. Canandaigua National Corp now owns 18,086 shares of the company's stock valued at $734,000 after purchasing an additional 468 shares during the period. Finally, Front Row Advisors LLC grew its stake in shares of Roche by 135.1% in the first quarter. Front Row Advisors LLC now owns 870 shares of the company's stock valued at $35,000 after buying an additional 500 shares in the last quarter. Institutional investors own 0.32% of the company's stock.

About Roche

Roche Holding AG operates as a research healthcare company. It operates through the following segments: Diagnostics and Pharmaceuticals. The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience. The Diagnostic segment refers to diagnosis of diseases through an in vitro diagnostics process.

Featured Story: What is range trading?

The Fly logo

Analyst Recommendations for Roche (OTCMKTS:RHHBY)


Featured Article: What is FinTech?

7 Stocks to Buy Now and Avoid a Summer Swoon







MarketBeat - Stock Market News and Research Tools logo


MarketBeat is accredited by the Better Business Bureau


